Gut Microbiota and Thyroid Health: What We Know

Gut bacteria may help recycle thyroid hormone after the liver sends hormone metabolites into bile. That idea makes the gut-thyroid axis biologically interesting—and commercially irresistible. But a plausible mechanism is not a treatment. Human studies have not shown that fixing the gut barrier, changing the microbiome, or taking a probiotic improves TSH, free T4, or free T3 in Hashimoto's thyroiditis or hypothyroidism.

The useful conclusion is narrower: thyroid hormones affect the gut, gut microbes may participate in thyroid-hormone recycling, and autoimmune thyroid disease can coincide with markers of impaired intestinal barrier function. None of that establishes that "leaky gut" causes hypothyroidism or that a probiotic can correct it.

How gut bacteria could affect thyroid hormone economy

A 2026 review of the gut-thyroid axis by Acampora et al. describes a bidirectional system. Thyroid hormones help regulate intestinal epithelial renewal and the organization of tight-junction proteins, including claudins, occludin, and ZO-1. Those proteins help control what crosses the intestinal lining.

The review also outlines an enterohepatic recycling pathway. The body can conjugate thyroid-hormone metabolites and excrete them in bile. Gut microbes carry enzymes that can deconjugate some of these compounds, potentially allowing reabsorption in the intestine. If that pathway materially contributes to thyroid-hormone turnover, changes in gut microbial activity could affect hormone economy.

That is the hypothesis. The quantitative human question remains unanswered: no available pharmacokinetic study reports what fraction of T4 or T3 turnover depends on bacterial deconjugation and intestinal reabsorption. No randomized trial has tested whether improving barrier function raises circulating thyroid hormone levels. You cannot responsibly turn this mechanism into a percentage, a protocol, or a supplement recommendation.

The direction also runs the other way. Hypothyroidism changes gastrointestinal motility and can cause constipation; hyperthyroidism can cause diarrhea. Thyroid status may therefore alter the intestinal environment and microbiota. Observational studies of dysbiosis in thyroid disease face a basic problem: the thyroid disorder may be driving the gut finding.

The one direct human barrier study points to Graves' disease

The most direct human evidence comes from Zheng et al.'s 2022 cross-sectional case-control study in Graves' disease, an autoimmune cause of hyperthyroidism. Compared with healthy controls, patients with Graves' disease had higher circulating lipopolysaccharide-binding protein, intestinal fatty acid-binding protein, and zonulin. These biomarkers are consistent with increased intestinal permeability and bacterial translocation.

The finding deserves neither dismissal nor overinterpretation. It is an association between Graves' disease and circulating biomarkers, not proof that a damaged intestinal barrier caused the disease. The study did not examine people with hypothyroidism or Hashimoto's thyroiditis, did not establish whether permeability markers tracked thyroid-hormone concentrations, and cannot determine which change came first.

It also complicates the popular claim that impaired gut integrity causes low thyroid hormone through failed recycling. The observed biomarker elevations occurred in hyperthyroid Graves' disease, not in hypothyroidism. Hyperthyroidism can accelerate intestinal transit, so altered barrier markers could be a downstream effect of thyroid excess. Different diseases can involve different mechanisms, but this study does not support a simple "leaky gut lowers thyroid hormone" story.

Elevated permeability biomarkers in Graves' disease are a clue worth studying, not evidence that gut repair treats thyroid dysfunction.

Micronutrients matter, but the gut-barrier link is unproven

Iodine is required to make thyroid hormone. Selenium supports selenoenzymes involved in thyroid-hormone metabolism and antioxidant defense, including deiodinases, thioredoxin reductase, and glutathione peroxidase. Iron and zinc also commonly enter the broader thyroid-nutrition conversation.

A 2025 systematic review and meta-analysis by Lopes et al. found that iodine nutritional status was associated at the population level with deficiencies in selenium, iron, and zinc. The review supports the practical point that micronutrient deficiencies can cluster and that selenium has a direct role in thyroid physiology.

It does not show that intestinal permeability causes poor iodine, selenium, iron, or zinc status. It did not measure gut-barrier function as a mediator. A person with a thyroid disorder should not assume that a gut test explains a nutrient deficiency, or that a supplement can replace evaluation of diet, medication use, gastrointestinal disease, and thyroid treatment.

Selenium and iodine deserve particular restraint because excess can cause harm. The evidence supports identifying and correcting deficiency with appropriate clinical guidance; it does not support indiscriminate high-dose supplementation in the name of microbiome optimization.

Why general gut-health research does not answer the thyroid question

There are randomized trials showing that food and microbiome interventions can change gut-related outcomes in other populations. For example, a 45-day randomized trial comparing 80 g daily of oats with rice enrolled 210 mildly hypercholesterolemic Chinese adults. Both groups lowered total and non-HDL cholesterol after 30 and 45 days, but the reductions were greater with oats at day 45 (p=0.011 for total cholesterol and p=0.049 for non-HDL cholesterol). Oat consumption also increased Akkermansia muciniphila and Roseburia and altered short-chain fatty-acid-related measures.

Those results support eating fiber-rich foods for reasons that have nothing to do with a speculative thyroid rescue pathway. The trial did not enroll people with thyroid disease and did not measure TSH, free T4, or free T3.

Likewise, a 2025 systematic review of prebiotics in healthy humans reported that non-digestible carbohydrates such as inulin, galactooligosaccharides, and fructooligosaccharides can influence microbiota, immune markers, inflammation, infection outcomes, and vaccine responses. The authors discuss short-chain fatty acids and potential effects on epithelial and immune cells. These are gut and immune findings, not evidence of thyroid treatment.

A separate network meta-analysis of 15 randomized trials involving 820 children and adolescents with overweight or obesity found that multiple-strain probiotics reduced BMI by 2.13 kg/m² versus comparator, with a 95% credible interval of -2.70 to -1.57 kg/m². It also reported changes in waist circumference, lipids, leptin, and high-sensitivity C-reactive protein. Those endpoints may be relevant to cardiometabolic health in that population, but they do not establish a thyroid effect.

The same principle applies to trials in other diseases. In a six-month double-blind trial, Escouto et al. randomized 48 people with nonalcoholic steatohepatitis to daily Lactobacillus acidophilus and Bifidobacterium lactis at 1 × 10⁹ colony-forming units each or placebo. The study assessed hepatic fibrosis, inflammatory and metabolic markers, and microbiota. It cannot tell us whether those strains affect thyroid hormone levels in Hashimoto's disease.

What the evidence supports today

For someone with diagnosed hypothyroidism or Hashimoto's, established care remains the foundation: take prescribed levothyroxine consistently, monitor thyroid tests with a clinician, and address documented nutrient deficiencies. Do not reduce or stop thyroid medication because a stool test or a supplement label promises hormonal "optimization."

General dietary habits that support gastrointestinal health—adequate fiber, legumes, vegetables, fruit, and fermented foods if tolerated—are reasonable on their own merits. They may improve diet quality and microbial metabolites, but they are not a proven thyroid intervention. A probiotic could be chosen for a separate, evidence-based indication; no strain, dose, or formulation can currently be recommended to improve TSH, free T4, or free T3.

The study that would change this conclusion is straightforward in design, if not execution: a sufficiently large placebo-controlled trial in people with Hashimoto's disease that measures TSH, free T4, free T3, and validated intestinal-permeability markers before and after a defined microbiome intervention. Until then, the gut-thyroid axis is a credible research framework with an empty clinical toolbox.